 Thanks, Teri. And I'd like to also thank all of you for taking time out of your schedules to come to this meeting of Genome Medicine 9, and just a reminder that all of the materials from the meeting are actually available on a website at the NHGRI website, so the materials and the presentations are accessible from there even after the meeting is over. And I just wanted to start with a little bit of introduction to the meeting itself. So all of us have seen this graphic many times over the past couple of years, representing the valley of death as it's called between basic science and clinical applications of basic science. And I think in the past couple of years, especially in Genome Medicine, there are some cases of successful traversal of this bridge. In cancer, for example, the emergence of targeted therapies based on genomic evidence, the development of tools and technologies to enable translation of genome information into diagnostics, into clinical practice. There are a few wonderful use cases to illustrate that this bridge can, in fact, be traversed successfully. But it's not necessarily a straight shot. So there's a lot of handoff points going from basic science into clinical relevance. And some of these in Genome Medicine at least appear to be lost in translation. There's needs to be translation of discovery from model systems to the relevance to human and back again. There's then the need to translate some of these findings from basic science to specific populations of patients. And then the translation of the information and knowledge into actual clinical practice. And at each of these handoff points, there are specific challenges and needs. And the communities are often not in perfect alignment to make that possible. So for this meeting, for Genomic Medicine, number nine, we're going to focus on one of the particular challenges along this path from basic science to clinical relevance. And that is understanding these variants of uncertain significance. So genome technologies have really revolutionized approach. We've been generating, as a community, very large data sets of DNA sequence from patient populations, but only a small handful of the variants that are discovered as a result of these large-scale genomic initiatives actually have enough knowledge, enough evidence that they can be translated into something that does have relevance to human health. So the objectives of this meeting are really to discuss the gaps, the technologies, and also some use cases of how these handoffs and this bridge from basic science to clinical relevance have been successfully traversed. What can we learn from those use cases? How can we, what do we need to do to better align basic research with clinical medicine in the area of genomics? Those are the kinds of things that we're wanting to come out of this meeting today. And so for the topics that we're going to discuss, it's going to be quite wide-ranging. There are going to be, as I said, sort of some talks this morning to set the stage from the basic science perspective and from the clinical perspective about where those gaps are. There's going to be some presentations about the successful bridging between basic science and bench and back again. And then we're going to talk about some of the technologies and tools that are being developed and need to be developed further to help facilitate these lines of communication and alignment of research. One of the things that we're not going to talk about though, just we're not going to touch much at this meeting on kind of the regulatory hurdles and the payer issues. Those are very important and large gaps and transition points along this trajectory. But we felt it was important to focus our discussions. And those were things that, if we had a week, maybe, but we have two days or a day and a half. So when we were planning this meeting with the members of the Genomic Medicine Working Group, we had, as our informal tag, bench-to-bedside, mind-to-gaps. But as Teri has shown you, from the past genomic medicine meetings, oftentimes what spins out of these are initiatives that are really powerful and productive in addressing the issues. So we're hoping that when we look back at this in another year that instead of mind-to-gaps, it'll be amend-to-gaps that will come out with some ideas and that might spin off into initiatives that will actually help us address some of these transition points that are vexing us and translating. So before I hand it over to Dan Rodin to moderate the first session, or actually hand it off to Eric in case he has a few comments to say, I do want to acknowledge the efforts of a number of people who brought this together, specifically Rita, Rita Chambers in the back here with her broken elbow, Teji, Ellie. Members of the Genomic Medicine Working Group who are really instrumental in putting together the agenda that we have today, our technology team for setting up the webcasting and the audio portion of the meeting. Without these guys, this meeting wouldn't have happened, so I really want to congratulate them and thank them for their efforts for this meeting. So with that, I'm looking forward to a very productive couple of days. Thank you again all for coming, and Eric, I turned it over to you.